Japanese Committee Recommends Approval For Novo Nordisk's Victoza And Novartis' Galvus
This article was originally published in PharmAsia News
Executive Summary
The First Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare approved Nov. 27 Victoza (liraglutide) injection and Galvus (vildagliptin) for type 2 diabetes
The First Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare approved Nov. 27 Victoza (liraglutide) injection and Galvus (vildagliptin) for type 2 diabetes. Novo Nordisk's liraglutide is the first approved CLP-agonist in Japan. Manufactured by Novartis, vildagliptin is the second DPP-4 inhibitor, approved after Banyu/Merck's Januvia . The same committee also approved Shionogi's antidepressant Cymbalta (duloxetine ). Shionogi will co-promote the serotonin-norepinephrine reuptake inhibitor agent with Eli Lilly Japan. (Click here for more - Japanese language) "Two Drugs Obtain Approval For Incretin Associated Type 2 Diabetes" - CB News (11/27/2009) |